Related references
Note: Only part of the references are listed.T Cell Dysfunction and Exhaustion in Cancer
Zhen Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target
Dongming Chen et al.
JOURNAL OF MEDICAL GENETICS (2019)
HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival
Han Yan et al.
CANCER LETTERS (2019)
Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease
Guochun Chen et al.
KIDNEY INTERNATIONAL (2019)
Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients
Lujun Chen et al.
CANCER CELL INTERNATIONAL (2019)
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes
M. Angela Aznar et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma
Xinfeng Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma
Ziwen Zhu et al.
ONCOTARGETS AND THERAPY (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status
Haiying Cheng et al.
CLINICAL CANCER RESEARCH (2017)
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3
Murali Janakiram et al.
IMMUNOLOGICAL REVIEWS (2017)
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Y. Liu et al.
ONCOGENE (2017)
Clinical Development of PD-1/ PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes
Ian Chau
CLINICAL CANCER RESEARCH (2017)
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Atsuko Kitano et al.
ESMO OPEN (2017)
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
Silvia Darb-Esfahani et al.
ONCOTARGET (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
Yaqi Li et al.
MOLECULAR CANCER (2016)
Targeting renal cell carcinoma with a HIF-2 antagonist
Wenfang Chen et al.
NATURE (2016)
Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer
Angel Diaz-Lagares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
Zheng Wang et al.
OncoImmunology (2016)
CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma
Guang-Tao Yu et al.
ONCOIMMUNOLOGY (2016)
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
Pratistha Koirala et al.
SCIENTIFIC REPORTS (2016)
Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
Brian Shuch et al.
EUROPEAN UROLOGY (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Co-stimulatory blockade of the CD28/CD80-86/CTLA-4 balance in transplantation: impact on memory T cells?
Simon Ville et al.
FRONTIERS IN IMMUNOLOGY (2015)
HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families
Murali Janakiram et al.
ONCOIMMUNOLOGY (2015)
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
Murali Janakiram et al.
CLINICAL CANCER RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions
Tai Hato et al.
HEPATOLOGY (2014)
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function
Ruihua Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
B7-H5 costimulates human T cells via CD28H
Yuwen Zhu et al.
NATURE COMMUNICATIONS (2013)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease
Eoin F. McKinney et al.
NATURE MEDICINE (2010)
Tissue microarrays (TMAs) for high-throughput molecular pathology research
A Nocito et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
